Loading

GeneVentiv Therapeutics, Inc.

June 05, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders. Our lead program, GENV-HEM, is the first AAV-based gene therapy to treat 33% of hemophilia patients (50K developed world) with neutralizing antibodies (inhibitors) to their missing clotting factor. GENV-HEM is also the first universal gene therapy for hemophilia, which has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.
GeneVentiv Therapeutics, Inc.
Company Website: http://www.geneventiv.com
Lead Product in Development: GENV-HEM, is the first, single infusion, AAV-based gene therapy to treat 33% of hemophilia patients with neutralizing antibodies (inhibitors) to their missing clotting factor (50K developed world patients). GENV-HEM is also the first universal gene therapy for all hemophilias, has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.

Company HQ City

Raleigh

Company HQ State

NC

Company HQ Country

United States

CEO/Top Company Official

Damon R. Race

Development Phase of Primary Product

Pre-Clinical
Speakers
Damon Race, MBA
CEO
GeneVentiv Therapeutics, Inc.
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS